大单品依赖明显,流感特效药龙头东阳光药冲刺港交所

北京商报
19 Jun

作为东阳光长江药业(01558.HK)的母公司,广东东阳光药业股份有限公司(以下简称“东阳光药”)正在筹划吸收合并东阳光长江药业并上市。港交所官网显示,东阳光药于近日递交了港股上市申请,拟以介绍方式在香港主板上市,中金公司担任独家保荐人。东阳光药因流感特效药而被市场所熟知,且公司逾六成营收来自大单品磷酸奥司他韦。随着抗流感药物市场竞争日趋激烈,东阳光药磷酸奥司他韦的优势能否持续值得关注。业绩方面,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10